• Teleflex Reports Third Quarter Financial Results and Full Year 2024 Outlook

    Source: Nasdaq GlobeNewswire / 31 Oct 2024 05:30:01   America/Chicago

    WAYNE, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the third quarter ended September 29, 2024.

    Third quarter financial summary

    • GAAP revenue of $764.4 million, up 2.4% compared to the prior year period, up 2.2% on a constant currency basis
    • GAAP diluted EPS from continuing operations of $2.36, compared to $2.91 in the prior year period
    • Adjusted diluted EPS from continuing operations of $3.49, compared to $3.64 in the prior year period

    2024 guidance summary

    • Lowering GAAP revenue growth guidance range to 2.90% to 3.40%
    • Lowering adjusted constant currency revenue growth guidance range to 3.50% to 4.00%
    • Raising GAAP EPS from continuing operations guidance range to $6.65 to $6.95
    • Raising the low end of adjusted diluted EPS from continuing operations guidance range to $13.90 to $14.20

    "In the third quarter, we delivered year-over-year margin expansion and continued adjusted operating income growth" said Liam Kelly, Teleflex's Chairman, President and Chief Executive Officer. "The benefits of our diversified portfolio were evident as strong performances from Interventional and Vascular Access helped offset unexpected softness in OEM revenues. Healthy revenue momentum for Barrigel continued while our integration of Palette Life Sciences AB remained on schedule. Cash flow remains strong, and we have augmented our disciplined capital allocation strategy with a $500 million share repurchase authorization, including a $200 million accelerated share program in the third quarter. With net leverage at 1.7x, we continue to have considerable balance sheet flexibility to execute on our M&A strategy. Finally, we have raised the low end of our 2024 adjusted EPS guidance.”

    NET REVENUE BY SEGMENT
    The following table provides information regarding net revenues in each of the Company's reportable operating segments for the three and nine months ended September 29, 2024 and the comparable prior year periods on a GAAP, adjusted and adjusted constant currency basis.

     Three Months Ended
     As reported Adjusted
     September 29, 2024 October 1, 2023 Reported Revenue Growth September 29, 2024 October 1, 2023 Adjusted Constant Currency Revenue Growth
    Americas$433.3 $428.2 1.2% $433.3 $428.2 1.5%
    EMEA150.2 142.7 5.3% 150.2 142.7 3.9%
    Asia98.3 93.2 5.5% 98.3 93.2 5.0%
    OEM82.6 82.3 0.3% 82.6 82.3 0.1%
    Consolidated$764.4 $746.4 2.4% $764.4 $746.4 2.2%


     Nine Months Ended
     As reported Adjusted
     September 29, 2024 October 1, 2023 Reported Revenue Growth September 29, 2024 October 1, 2023 Adjusted Constant Currency Revenue Growth
    Americas$1,266.4 $1,264.7 0.1% $1,266.4 $1,264.7 0.2%
    EMEA456.9 433.9 5.3% 470.7 433.9 7.8%
    Asia269.5 258.6 4.2% 269.5 258.6 6.5%
    OEM259.1 243.4 6.4% 259.1 243.4 6.3%
    Consolidated$2,251.9 $2,200.6 2.3% $2,265.7 $2,200.6 3.1%


    NET REVENUE BY GLOBAL PRODUCT CATEGORY
    The following table provides information regarding net revenues in each of the Company's global product categories for the three and nine months ended September 29, 2024 and the comparable prior year periods on a GAAP, adjusted and adjusted constant currency basis.

     Three Months Ended
     As reported Adjusted
     September 29, 2024 October 1, 2023 Reported Revenue Growth September 29, 2024 October 1, 2023 Adjusted Constant Currency Revenue Growth
    Vascular Access$180.9 $169.9 6.5% $180.9 $169.9 6.3%
    Interventional149.9 134.1 11.8% 149.9 134.1 11.4%
    Anesthesia101.1 97.6 3.6% 101.1 97.6 3.4%
    Surgical111.7 112.8 (0.9)% 111.7 112.8 (1.0)%
    Interventional Urology83.4 73.6 13.3% 83.4 73.6 13.3%
    OEM82.6 82.3 0.3% 82.6 82.3 0.1%
    Other54.8 76.1 (28.0)% 54.8 76.1 (28.3)%
    Consolidated$764.4 $746.4 2.4% $764.4 $746.4 2.2%


     Nine Months Ended
     As reported Adjusted
     September 29, 2024 October 1, 2023 Reported Revenue Growth September 29, 2024 October 1, 2023 Adjusted Constant Currency Revenue Growth
    Vascular Access$543.3 $521.3 4.2% $543.3 $521.3 4.3%
    Interventional425.7 375.8 13.3% 425.7 375.8 13.4%
    Anesthesia300.0 291.8 2.8% 300.0 291.8 2.9%
    Surgical328.6 317.8 3.4% 328.6 317.8 4.0%
    Interventional Urology246.2 226.8 8.6% 246.2 226.8 8.8%
    OEM259.1 243.4 6.4% 259.1 243.4 6.3%
    Other (1)149.0 223.7 (33.4)% 162.8 223.7 (27.3)%
    Consolidated$2,251.9 $2,200.6 2.3% $2,265.7 $2,200.6 3.1%

    (1) In 2024, amounts reflect the impact from increases in our reserves related to the Italian payback measure pertaining to prior years.

    OTHER FINANCIAL HIGHLIGHTS

    • Depreciation expense, amortization of intangible assets and deferred financing charges for the nine months ended September 29, 2024 totaled $205.4 million compared to $180.5 million for the prior year period.
    • Total cash, cash equivalents and restricted cash equivalents at September 29, 2024 were $277.8 million compared to $222.8 million at December 31, 2023.
    • Net accounts receivable at September 29, 2024 were $470.3 million compared to $443.5 million at December 31, 2023.
    • Inventories at September 29, 2024 were $639.9 million compared to $626.2 million at December 31, 2023.

    2024 OUTLOOK
    The Company lowered its full year 2024 revenue growth outlook on a GAAP basis from a range of 3.40% to 4.40% to a range of 2.90% to 3.40%, including our estimate of an approximately 0.15% negative impact of foreign exchange rate fluctuations. On an adjusted constant currency basis, the Company lowered its full year 2024 revenue growth outlook from a range of 4.25% to 5.25% to a range of 3.50% to 4.00% year-over-year.

    The Company raised its full year 2024 GAAP diluted earnings per share from continuing operations outlook from a range of $6.43 to $6.83 to a range of $6.65 to $6.95, representing a year-over-year change of (12.0)% to (8.1)%. The Company raised the low end of its full year 2024 adjusted diluted earnings per share from continuing operations guidance from a range of $13.80 to $14.20 to a range of $13.90 to $14.20, representing growth of 2.8% to 5.0% year-over-year.

    Forecasted 2024 Adjusted Constant Currency Revenue Growth Reconciliation

     Low High
    Forecasted 2024 GAAP revenue growth2.90% 3.40%
    Estimated impact of foreign currency exchange rate fluctuations(0.15)% (0.15)%
    Italian payback measure(0.45)% (0.45)%
    Forecasted 2024 adjusted constant currency revenue growth3.50% 4.00%
     

    Forecasted 2024 Adjusted Diluted Earnings Per Share From Continuing Operations Reconciliation

     Low High
    Forecasted GAAP diluted earnings per share from continuing operations$6.65 $6.95
    Restructuring, restructuring related and impairment items, net of tax$0.60 $0.60
    Acquisition, integration and divestiture related items, net of tax$0.30 $0.30
    Pension termination and related charges, net of tax$1.70 $1.70
    ERP Implementation, net of tax$0.32 $0.32
    MDR, net of tax$0.18 $0.18
    Italian payback measure, net of tax$0.29 $0.29
    Intangible amortization expense, net of tax$3.81 $3.81
    Tax adjustments$0.05 $0.05
    Forecasted adjusted diluted earnings per share from continuing operations, net of tax$13.90 $14.20
     

    CONFERENCE CALL WEBCAST AND ADDITIONAL INFORMATION
    A webcast of Teleflex's third quarter 2024 investor conference call can be accessed live from a link on the Company's website at teleflex.com. The call will begin at 8:00 am ET on October 31, 2024.

    An audio replay of the investor call will be available beginning at 11:00 am ET on October 31, 2024, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The confirmation code is 69028.

    ADDITIONAL NOTES
    References in this release to the impact of foreign currency exchange rate fluctuations on adjusted diluted earnings per share include both the impact of translating foreign currencies into U.S. dollars and the impact of foreign currency exchange rate fluctuations on foreign currency denominated transactions.

    In the discussion of segment results, "new products" refers to products for which we initiated commercial sales within the past 36 months and "existing products" refers to products we have sold commercially for more than 36 months.

    Certain financial information is presented on a rounded basis, which may cause minor differences. Segment results and commentary exclude the impact of discontinued operations.

    NOTES ON NON-GAAP FINANCIAL MEASURES
    We report our financial results in accordance with accounting principles generally accepted in the United States, commonly referred to as “GAAP”. In this press release, we provide supplemental information, consisting of the following non-GAAP financial measures: adjusted revenue, adjusted constant currency revenue growth and adjusted diluted earnings per share. These non-GAAP measures are described in more detail below. Management uses these financial measures to assess Teleflex’s financial performance, make operating decisions, allocate financial resources, provide guidance on possible future results, and assist in its evaluation of period-to-period and peer comparisons. The non-GAAP measures may be useful to investors because they provide insight into management’s assessment of our business, and provide supplemental information pertinent to a comparison of period-to-period results of our ongoing operations. The non-GAAP financial measures are presented in addition to results presented in accordance with GAAP and should not be relied upon as a substitute for GAAP financial measures. Moreover, our non-GAAP financial measures may not be comparable to similarly titled measures used by other companies.

    Tables reconciling changes in historical adjusted constant currency net revenues and adjusted net revenues to historical GAAP net revenues and historical adjusted diluted earnings per share from continuing operations to historical GAAP diluted earnings per share from continuing operations are set forth below.

    Adjusted revenue: This non-GAAP measure is based upon net revenues, adjusted to exclude the impact in the nine months ended September 29, 2024 of an increase in our reserves, and corresponding reduction to revenue within our EMEA segment, for prior years. The reserve relates to the Italian payback measure, a law that requires suppliers of medical devices to the Italian National Healthcare System to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. As a result of a recent ruling from the Italian courts, we recognized an increase in our reserves during the nine months ended September 29, 2024, of which $13.8 million related to prior years. The prior year amounts do not represent normal adjustments to revenue, are not expected to recur in future periods and are not recurring in nature, making it difficult to contribute to a meaningful evaluation of our operating performance. Accordingly, management has excluded the $13.8 million prior year amount as it is not indicative of our underlying core performance or business trends.

    Adjusted constant currency revenue growth: This non-GAAP measure is based upon net revenues, adjusted to exclude, depending on the period presented, the items described in Adjusted revenue and to eliminate the impact of translating the results of international subsidiaries at different currency exchange rates from period to period. The impact of changes in foreign currency may vary significantly from period to period, and such changes generally are outside of the control of our management. We believe that this measure facilitates a comparison of our operating performance exclusive of currency exchange rate fluctuations that do not reflect our underlying performance or business trends.

    Adjusted diluted earnings per share: This non-GAAP measure is based upon diluted earnings per share from continuing operations, the most directly comparable GAAP measure, adjusted to exclude, depending on the period presented, the items described below. Management does not believe that any of the excluded items are indicative of our underlying core performance or business trends.

    Restructuring, restructuring related and impairment items - Restructuring programs involve discrete initiatives designed to, among other things, consolidate or relocate manufacturing, administrative and other facilities, outsource distribution operations, improve operating efficiencies and integrate acquired businesses. Depending on the specific restructuring program involved, our restructuring charges may include employee termination, contract termination, facility closure, employee relocation, equipment relocation, outplacement and other exit costs associated with the restructuring program. Restructuring related charges are directly related to our restructuring programs and consist of facility consolidation costs, including accelerated depreciation expense related to facility closures, costs to transfer manufacturing operations between locations, and retention bonuses offered to certain employees as an incentive for them to remain with our company after completion of the restructuring program. Impairment charges occur if, due to events or changes in circumstances, we determine that the carrying value of an asset exceeds its fair value. Impairment charges do not directly affect our liquidity, but could have a material adverse effect on our reported financial results.

    Acquisition, integration and divestiture related items - Acquisition and integration expenses are incremental charges, other than restructuring or restructuring related expenses, that are directly related to specific business or asset acquisition transactions. These charges may include, among other things, professional, consulting and other fees; systems integration costs; inventory step-up amortization (amortization, through cost of goods sold, of the increase in fair value of inventory resulting from a fair value calculation as of the acquisition date); fair value adjustments to contingent consideration liabilities; and bridge loan facility and backstop financing fees in connection with loan facilities that ultimately were not utilized. Divestiture related activities involve specific business or asset sales. Depending primarily on the terms of a divestiture transaction, the carrying value of the divested business or assets on our financial statements and other costs we incur as a direct result of the divestiture transaction, we may recognize a gain or loss in connection with the divestiture related activities.

    Italian payback measure - These adjustments represent the exclusion of the impact from increases in our reserves related to the Italian payback measure pertaining to prior years as described in Adjusted revenue.

    Pension termination and related charges - These adjustments represent charges associated with the planned termination of the Teleflex Incorporated Retirement Income Plan, a frozen U.S. defined benefit pension plan, and related direct incremental expenses including certain charges stemming from the liquidation of surplus plan assets. These charges and costs do not represent normal and recurring operating expenses, will be inconsistent in amounts and frequency, and are not expected to recur once the plan termination process has been completed. Accordingly, management has excluded these amounts to facilitate an evaluation of our current operating performance and a comparison to our past operating performance.

    European medical device regulation - The European Union (“EU”) has adopted the EU Medical Device Regulation (“MDR”), which replaces the existing Medical Devices Directive (“MDD”) and imposes more stringent requirements for the marketing and sale of medical devices in the EU, including requirements affecting clinical evaluations, quality systems and post-market surveillance. The MDR requirements became effective in May 2021, although certain devices that previously satisfied MDD requirements can continue to be marketed in the EU until December 2027 for highest-risk devices and December 2028 for lower-risk devices, subject to certain limitations. Significantly, the MDR will require the re-registration of previously approved medical devices. As a result, Teleflex will incur expenditures in connection with the new registration of medical devices that previously had been registered under the MDD. Therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters (in contrast, no adjustment has been made to exclude expenditures related to the registration of medical devices that were not registered previously under the MDD).

    Intangible amortization expense - Certain intangible assets, including customer relationships, intellectual property, distribution rights, trade names and non-competition agreements, initially are recorded at historical cost and then amortized over their respective estimated useful lives. The amount of such amortization can vary from period to period as a result of, among other things, business or asset acquisitions or dispositions.

    ERP implementation - These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance.

    Tax adjustments - These adjustments represent the impact of the expiration of applicable statutes of limitations for prior year returns, the resolution of audits, the filing of amended returns with respect to prior tax years and/or tax law or certain other discrete changes affecting our deferred tax liability.

    Reconciliation of Net Revenue (Dollars in millions)

    Net revenue by segment

     Three Months Ended % Increase / (Decrease)
     September 29, 2024 October 1, 2023 
     Reported revenue Adjustment Adjusted Revenue Reported revenue Adjustment Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment impact Adjusted Constant Currency Revenue Growth
    Americas$433.3 $— $433.3 $428.2 $— $428.2 1.2% (0.3)% —% 1.5%
    EMEA150.2 — 150.2 142.7 — 142.7 5.3% 1.4% —% 3.9%
    Asia98.3 — 98.3 93.2 — 93.2 5.5% 0.5% —% 5.0%
    OEM82.6 — 82.6 82.3 — 82.3 0.3% 0.2% —% 0.1%
    Consolidated$764.4 $— $764.4 $746.4 $— $746.4 2.4% 0.2% —% 2.2%


     Nine Months Ended % Increase / (Decrease)
     September 29, 2024 October 1, 2023 
     Reported revenue Adjustment Adjusted Revenue Reported revenue Adjustment Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment impact Adjusted Constant Currency Revenue Growth
    Americas$1,266.4 $— $1,266.4 $1,264.7 $— $1,264.7 0.1% (0.1)% —% 0.2%
    EMEA456.9 (13.8) 470.7 433.9 — 433.9 5.3% 0.7% (3.2)% 7.8%
    Asia269.5 — 269.5 258.6 — 258.6 4.2% (2.3)% —% 6.5%
    OEM259.1 — 259.1 243.4 — 243.4 6.4% 0.1% —% 6.3%
    Consolidated$2,251.9 ($13.8) $2,265.7 $2,200.6 $— $2,200.6 2.3% (0.2)% (0.6)% 3.1%


    Net revenue by global product category

     Three Months Ended % Increase / (Decrease)
     September 29, 2024 October 1, 2023 
     Reported revenue Adjustment Adjusted Revenue Reported revenue Adjustment Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment impact Adjusted Constant Currency Revenue Growth
    Vascular Access$180.9 $— $180.9 $169.9 $— $169.9 6.5% 0.2% —% 6.3%
    Interventional149.9 — 149.9 134.1 — 134.1 11.8% 0.4% —% 11.4%
    Anesthesia101.1 — 101.1 97.6 — 97.6 3.6% 0.2% —% 3.4%
    Surgical111.7 — 111.7 112.8 — 112.8 (0.9)% 0.1% —% (1.0)%
    Interventional Urology83.4 — 83.4 73.6 — 73.6 13.3% —% —% 13.3%
    OEM82.6 — 82.6 82.3 — 82.3 0.3% 0.2% —% 0.1%
    Other (1)54.8 — 54.8 76.1 — 76.1 (28.0)% 0.3% —% (28.3)%
    Consolidated$764.4 $— $764.4 $746.4 $— $746.4 2.4% 0.2% —% 2.2%


     Nine Months Ended % Increase / (Decrease)
     September 29, 2024 October 1, 2023 
     Reported revenue Adjustment Adjusted Revenue Reported revenue Adjustment Adjusted Revenue Reported Revenue Growth Currency Impact Adjustment impact Adjusted Constant Currency Revenue Growth
    Vascular Access$543.3 $— $543.3 $521.3 $— $521.3 4.2% (0.1)% —% 4.3%
    Interventional425.7 — 425.7 375.8 — 375.8 13.3% (0.1)% —% 13.4%
    Anesthesia300.0 — 300.0 291.8 — 291.8 2.8% (0.1)% —% 2.9%
    Surgical328.6 — 328.6 317.8 — 317.8 3.4% (0.6)% —% 4.0%
    Interventional Urology246.2 — 246.2 226.8 — 226.8 8.6% (0.2)% —% 8.8%
    OEM259.1 — 259.1 243.4 — 243.4 6.4% 0.1% —% 6.3%
    Other (1)149.0 (13.8) 162.8 223.7 — 223.7 (33.4)% —% (6.1)% (27.3)%
    Consolidated$2,251.9 ($13.8) $2,265.7 $2,200.6 $— $2,200.6 2.3% (0.2)% (0.6)% 3.1%

    (1) In 2024, amounts reflect the impact from increases in our reserves related to the Italian payback measure pertaining to prior years.



    Reconciliation of Consolidated Statement of Income Items (Dollars in millions, except per share data)

    Three Months Ended September 29, 2024
     Revenue Gross
    margin    		 SG&A(1) R&D(1) Operating margin(2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations
    GAAP Basis$764.4 56.3% 31.6% 5.1% 19.5% $130.6 $19.6 15.0% $2.36
    Adjustments                 
    Restructuring, restructuring related and impairment items (A)— 0.7 (0.1) — 0.9 6.8 1.2   0.12
    Acquisition, integration and divestiture related items (B)— — (0.3) — 0.3 2.0 —   0.04
    ERP implementation— — (0.8) — 0.8 6.1 1.0   0.11
    MDR— — — (0.2) 0.2 1.3 —   0.03
    Pension termination costs  — 0.7 — (0.7) (5.4) (1.3)   (0.09)
    Intangible amortization expense— 3.8 (2.5) — 6.3 48.3 5.2   0.92
    Adjustments total— 4.5 (3.0) (0.2) 7.8 59.1 6.1   1.13
    Adjusted basis$764.4 60.8% 28.6% 4.9% 27.3% $189.7 $25.7 13.6% $3.49


    Three Months Ended October 1, 2023
     Gross margin SG&A(1) R&D(1) Operating margin(2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations
    GAAP Basis55.8% 28.6% 5.0% 22.1% $149.6 $11.9 8.0% $2.91
    Adjustments               
    Restructuring, restructuring related and impairment items (A)0.5 — — 0.6 4.7 0.7   0.08
    Acquisition, integration and divestiture related items (B)— 2.0 — (2.0) (14.8) 0.2   (0.32)
    ERP implementation— — — — 0.3 0.1   —
    MDR— — (0.8) 0.8 5.7 —   0.12
    Intangible amortization expense3.1 (2.6) — 5.7 41.6 2.1   0.85
    Tax adjustments— — — — — —   —
    Adjustments total3.6 (0.6) (0.8) 5.1 37.5 3.1   0.73
    Adjusted basis59.4% 28.0% 4.2% 27.2% $187.1 $15.0 8.0% $3.64


    Notes:(1)Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.
     (2) Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues.
       
    Totals may not sum due to rounding.

     


    Nine Months Ended September 29, 2024
     Revenue Gross margin SG&A(1) R&D(1) Operating margin(2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations
    GAAP Basis$2,251.9 56.1% 38.8% 5.2% 11.6% $202.2 $(4.6) (2.3)% $4.38
    Adjustments                 
    Restructuring, restructuring related and impairment items (A)— 0.5 (0.1) — 1.1 24.8 4.3   0.44
    Acquisition, integration and divestiture related items (B)— 0.1 (0.4) — 0.5 11.0 0.5   0.22
    Italian payback measure (C)13.8 0.2 (0.2) — 0.6 13.8 —   0.29
    ERP implementation— — (0.4) — 0.4 9.2 1.4   0.17
    MDR— — — (0.4) 0.3 7.6 —   0.16
    Pension termination costs— — (5.9) — 5.9 133.2 56.9   1.61
    Intangible amortization expense— 4.0 (2.6) — 6.5 148.0 15.2   2.81
    Tax adjustments— — — — — — (2.1)   0.04
    Adjustments total13.8 4.8 (9.6) (0.4) 15.3 347.6 76.2   5.74
    Adjusted basis$2,265.7 60.9% 29.2% 4.8% 26.9% $549.8 $71.6 13.0% $10.12


    Nine Months Ended October 1, 2023
     Gross margin SG&A (1) R&D (1) Operating margin (2) Income before income taxes Income tax expense Effective income tax rate Diluted earnings per share from continuing operations
    GAAP Basis55.2% 30.4% 5.4% 19.3% $374.0 $47.7 12.7% $6.90
    Adjustments               
    Restructuring, restructuring related and impairment items (A)0.9 — (0.1) 1.3 27.5 4.2   0.49
    Acquisition, integration and divestiture related items (B)— 0.9 — (0.9) (19.3) 0.3   (0.41)
    ERP implementation— (0.1) — 0.1 2.8 0.7   0.05
    MDR— — (1.1) 1.1 23.6 —   0.50
    Intangible amortization expense3.2 (2.6) — 5.6 125.3 6.2   2.51
    Tax adjustments— — — — — (4.8)   0.10
    Adjustments total4.1 (1.8) (1.2) 7.2 159.9 6.6   3.24
    Adjusted basis59.3% 28.6% 4.2% 26.5% $533.9 $54.3 10.2% $10.14


    Notes:(1)Selling, general and administrative expenses and research and development expenses are shown as a percentage of as reported and adjusted revenues.
     (2)Operating margin defined as Income from continuing operations before interest, loss on extinguishment of debt and taxes as a percentage of as reported and adjusted revenues.
       
    Totals may not sum due to rounding.

     
     

    Tickmarks to Reconciliation Tables
    (A)Restructuring, restructuring related and impairment items – For the three months ended September 29, 2024, pre-tax restructuring charges were $0.3 million and restructuring related charges were $6.5 million. For the three months ended October 1, 2023, pre-tax restructuring charges were $0.2 million and restructuring related charges were $4.5 million. For the nine months ended September 29, 2024, pre-tax restructuring charges were $8.7 million; restructuring related charges were $14.0 million; and impairment charges were $2.1 million. For the nine months ended October 1, 2023, pre-tax restructuring charges were $4.0 million and restructuring related charges were $23.6 million.
      
    (B)Acquisition, integration and divestiture related items – For the three and nine months ended September 29, 2024 and October 1, 2023, these charges related to changes in the estimated fair value of our contingent consideration liabilities and the acquisition of Palette Life Sciences AB.
      
    (C)Italian payback measure – Adjustment reflects the impact of an increase in reserves for prior years related to the Italian payback measure and its impact on the adjusted basis for each Non-GAAP financial measure presented within the table.
      

    ABOUT TELEFLEX INCORPORATED
    As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

    Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

    At Teleflex, we are empowering the future of healthcare. For more information, please visit teleflex.com.

    CAUTION CONCERNING FORWARD-LOOKING INFORMATION
    This press release contains forward-looking statements, including, but not limited to, our ability to execute on our M&A strategy; forecasted 2024 GAAP and adjusted constant currency revenue growth and GAAP and adjusted diluted earnings per share; and our estimates regarding the projected impact of foreign currency exchange rate fluctuations on our 2024 financial results. Actual results could differ materially from those in the forward-looking statements due to, among other things, delays or cancellations in shipments; demand for and market acceptance of new and existing products; our inability to provide products to our customers, which may be due to, among other things, events that impact key distributors, suppliers and third-party vendors that sterilize our products; our inability to integrate acquired businesses into our operations, realize planned synergies and operate such businesses profitably in accordance with our expectations; the inability of acquired businesses to generate revenues in accordance with our expectations; our inability to effectively execute our restructuring plans and programs; our inability to realize anticipated savings from restructuring plans and programs; the impact of healthcare reform legislation and proposals to amend, replace or repeal the legislation; changes in Medicare, Medicaid and third party coverage and reimbursements; the impact of enacted tax legislation and related regulations; competitive market conditions and resulting effects on revenues and pricing; increases in raw material costs that cannot be recovered in product pricing; global economic factors, including currency exchange rates, interest rates, trade disputes, sovereign debt issues and international conflicts and hostilities, such as the ongoing conflicts in the Ukraine and the Middle East; public health epidemics; difficulties in entering new markets; general economic conditions; and other factors described or incorporated in our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K. We expressly disclaim any obligation to update forward-looking statements, except as otherwise specifically stated by us or as required by law or regulation.


    TELEFLEX INCORPORATED
    CONSOLIDATED STATEMENTS OF INCOME
    (Unaudited)
     
     Three Months Ended Nine Months Ended
     September 29, 2024 October 1, 2023 September 29, 2024 October 1, 2023
     (Dollars and shares in thousands, except per share)
    Net revenues$764,375  $746,389  $2,251,915  $2,200,580 
    Cost of goods sold 334,203   330,078   989,151   985,066 
    Gross profit 430,172   416,311   1,262,764   1,215,514 
    Selling, general and administrative expenses 247,257   213,194   740,718   669,216 
    Research and development expenses 38,726   37,576   117,119   118,493 
    Pension settlement charge (5,407)  —   132,732   — 
    Restructuring and impairment charges 285   231   10,799   3,960 
    Income from continuing operations before interest and taxes 149,311   165,310   261,396   423,845 
    Interest expense 21,058   23,192   64,909   59,291 
    Interest income (2,298)  (7,487)  (5,751)  (9,486)
    Income from continuing operations before taxes 130,551   149,605   202,238   374,040 
    Taxes (benefit) on income from continuing operations 19,633   11,935   (4,586)  47,651 
    Income from continuing operations 110,918   137,670   206,824   326,389 
    Operating income (loss) from discontinued operations 112   (687)  (639)  (1,512)
    Taxes (benefit) on operating loss from discontinued operations 26   (157)  (146)  (346)
    Income (loss) from discontinued operations 86   (530)  (493)  (1,166)
    Net income$111,004  $137,140  $206,331  $325,223 
    Earnings per share:       
    Basic:       
    Income from continuing operations$2.37  $2.93  $4.40  $6.95 
    Income (loss) from discontinued operations 0.01   (0.01)  (0.01)  (0.03)
    Net income$2.38  $2.92  $4.39  $6.92 
    Diluted:       
    Income from continuing operations$2.36  $2.91  $4.38  $6.90 
    Loss from discontinued operations —   (0.01)  (0.01)  (0.02)
    Net income$2.36  $2.90  $4.37  $6.88 
    Weighted average common shares outstanding       
    Basic 46,724   46,992   46,995   46,974 
    Diluted 47,012   47,299   47,256   47,304 



    TELEFLEX INCORPORATED
    CONSOLIDATED BALANCE SHEETS
    (Unaudited)
     
     September 29, 2024 December 31, 2023
     (Dollars in thousands)
    ASSETS   
    Current assets   
    Cash and cash equivalents$243,235  $222,848 
    Accounts receivable, net 470,257   443,467 
    Inventories 639,938   626,216 
    Prepaid expenses and other current assets 116,928   107,471 
    Prepaid taxes 28,945   7,404 
    Total current assets 1,499,303   1,407,406 
    Property, plant and equipment, net 512,224   479,913 
    Operating lease assets 112,895   123,521 
    Goodwill 2,918,562   2,914,055 
    Intangible assets, net 2,325,105   2,501,960 
    Deferred tax assets 6,779   6,748 
    Other assets 111,423   98,943 
    Total assets$7,486,291  $7,532,546 
    LIABILITIES AND EQUITY   
    Current liabilities   
    Current borrowings$96,875  $87,500 
    Accounts payable 119,255   132,247 
    Accrued expenses 157,782   146,880 
    Payroll and benefit-related liabilities 142,619   146,535 
    Accrued interest 16,657   5,583 
    Income taxes payable 18,681   41,453 
    Other current liabilities 66,884   46,547 
    Total current liabilities 618,753   606,745 
    Long-term borrowings 1,661,546   1,727,572 
    Deferred tax liabilities 445,841   456,080 
    Pension and postretirement benefit liabilities 23,548   23,989 
    Noncurrent liability for uncertain tax positions 3,369   3,370 
    Noncurrent operating lease liabilities 102,938   111,300 
    Other liabilities 148,579   162,502 
    Total liabilities 3,004,574   3,091,558 
    Commitments and contingencies   
    Total shareholders' equity 4,481,717   4,440,988 
    Total liabilities and shareholders' equity$7,486,291  $7,532,546 


    TELEFLEX INCORPORATED
    CONSOLIDATED STATEMENTS OF CASH FLOWS
    (Unaudited)
     
     Nine Months Ended
     September 29, 2024 October 1, 2023
     (Dollars in thousands)
    Cash flows from operating activities of continuing operations:   
    Net income$206,331  $325,223 
    Adjustments to reconcile net income to net cash provided by operating activities:   
    Loss from discontinued operations 493   1,166 
    Depreciation expense 54,826   52,687 
    Intangible asset amortization expense 147,983   125,230 
    Deferred financing costs and debt discount amortization expense 2,562   2,547 
    Pension settlement charge 132,732   — 
    Fair value step up of acquired inventory sold 1,722   — 
    Changes in contingent consideration 7,446   (24,482)
    Assets impairment charge 2,110   — 
    Stock-based compensation 23,727   22,135 
    Deferred income taxes, net (60,648)  2,076 
    Payments for contingent consideration —   (289)
    Interest benefit on swaps designated as net investment hedges (12,031)  (15,459)
    Other 1,970   4,743 
    Changes in assets and liabilities, net of effects of acquisitions and disposals:   
    Accounts receivable (25,294)  (18,313)
    Inventories (11,635)  (50,702)
    Prepaid expenses and other assets 40,446   7,487 
    Accounts payable, accrued expenses and other liabilities (1,623)  (16,674)
    Income taxes receivable and payable, net (75,493)  (45,014)
    Net cash provided by operating activities from continuing operations 435,624   372,361 
    Cash flows from investing activities of continuing operations:   
    Expenditures for property, plant and equipment (94,412)  (63,768)
    Payments for businesses and intangibles acquired, net of cash acquired (120)  (205)
    Net proceeds on swaps designated as net investment hedges 18,262   10,275 
    Proceeds from sales of investments 7,300   7,300 
    Purchase of investments (7,300)  (11,300)
    Net cash used in investing activities from continuing operations (76,270)  (57,698)
    Cash flows from financing activities of continuing operations:   
    Proceeds from new borrowings 130,000   646,000 
    Reduction in borrowings (188,375)  (321,625)
    Repurchase of common stock (200,000)  — 
    Net proceeds from share based compensation plans and related tax impacts 3,555   534 
    Payments for contingent consideration (182)  (949)
    Dividends paid (47,808)  (47,919)
    Net cash (used in) provided by financing activities from continuing operations (302,810)  276,041 
    Cash flows from discontinued operations:   
    Net cash used in operating activities (2,355)  (579)
    Net cash used in discontinued operations (2,355)  (579)
    Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents 728   (660)
    Net increase in cash, cash equivalents and restricted cash equivalents 54,917   589,465 
    Cash, cash equivalents and restricted cash equivalents at the beginning of the period 222,848   292,034 
    Cash, cash equivalents and restricted cash equivalents at the end of the period$277,765  $881,499 
        

    Contacts:
    Teleflex Incorporated:
    Lawrence Keusch
    Vice President, Investor Relations and Strategy Development

    investors.teleflex.com
    610-948-2836


    Primary Logo

Share on,